Key result
Cannabis-related disorder in heart failure is linked to ~47% higher 1-year all-cause hospitalization.
Why the study?
The clinical implications of cannabis exposure on hospitalization and cardiovascular outcomes in patients with heart failure remain uncertain.
Does a documented cannabis-related disorder increase the risk of all-cause hospitalization and adverse cardiovascular outcomes at 1 year in adult patients with heart failure?
Cohort (n=61,248)
Yes
Does a documented cannabis-related disorder increase the risk of all-cause hospitalization and adverse cardiovascular outcomes at 1 year in adult patients with heart failure?
In a large propensity-matched cohort of patients with heart failure, a documented cannabis-related disorder was significantly associated with increased 1-year risks of all-cause hospitalization, mortality, stroke, and myocardial infarction.
Answers are grounded in this paper and cite their sources.
CRD was associated with higher all-cause hospitalization; hypothesis-generating for cannabis effects and should not yet change practice.
Background The clinical implications of cannabis exposure in patients with heart failure remain uncertain. We evaluated the associations between a documented cannabis-related disorder (CRD) and hospitalization and cardiovascular outcomes in a large real-world heart failure cohort. Methods We performed a retrospective cohort study using the TriNetX US Collaborative Network. Adult patients with heart failure (ICD-10-CM I50) were identified and stratified by the presence or absence of cannabis-related disorder (ICD-10-CM F12) recorded within 1 year on or before the first heart failure diagnosis, which served as the index date. The primary outcome was all-cause hospitalization at 1 year. Secondary outcomes included stroke, myocardial infarction, end-stage renal disease, atrial fibrillation/flutter, and all-cause mortality. Follow-up began 1 day after the index date; patients with a prior history of a given outcome were excluded from that analysis. One-to-one propensity score matching was performed using 26 baseline covariates. Results After matching, 30,624 patients were included in each cohort. At 1 year, a documented CRD was associated with a higher risk of hospitalization (57.5% vs. 45.1%; HR, 1.468; 95% CI, 1.436–1.501; p < 0.001). A documented CRD was also associated with significantly higher all-cause mortality (10.4% vs 9.3%; HR, 1.147; 95% CI, 1.090–1.207; p < 0.001), stroke (2.9% vs 2.3%; HR, 1.263; 95% CI, 1.138–1.401; p < 0.001), and myocardial infarction (6.0% vs 4.4%; HR, 1.415; 95% CI, 1.307–1.531; p < 0.001). Atrial fibrillation/flutter and end-stage renal disease did not differ. The hospitalization association persisted after excluding the first 30 days of follow-up (HR 1.252; 95% CI 1.226–1.280; p < 0.001), was similar in women and men, and remained in multivariable Cox models (adjusted HR 1.521; 95% CI 1.503–1.539; p < 0.001). Conclusions In this real-world propensity score–matched cohort of patients with heart failure, a documented cannabis-related disorder was associated with higher risks of hospitalization and selected adverse cardiovascular outcomes. Prospective studies with precise cannabis exposure characterization are needed to confirm these associations.
No takes yet. Share an insight, caveat, or question.
Dalal et al. (2026) conducted a cohort in Heart failure (n=61,248). Cannabis-related disorder (ICD-10-CM F12) vs. Absence of cannabis-related disorder was evaluated on All-cause hospitalization at 1 year (HR 1.468, 95% CI 1.436-1.501, p=<0.001). A documented cannabis-related disorder in heart failure patients was associated with higher 1-year all-cause hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: